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Abstract
Mycobacterial lung disease is caused by nontuberculous mycobacteria (NTM), also known as atypical mycobacteria. NTM are 
widely distributed in the environment, particularly in soil and water; they may colonize the airways, gastrointestinal tract and 
genitourinary system, without the apparent signs of disease. Nevertheless, in some risk groups such as patients with chronic lung 
diseases or with immunodeficiency, mycobacterial lung disease is identified. Recently, increased recognition of mycobacterial 
lung disease in chronic obstructive pulmonary disease (COPD) patients has been observed, especially in those treated with high 
doses of inhaled corticosteroids.
In the present paper, we describe the patient treated for many years due to COPD and bronchiectasis, with clinical and radiological 
picture suggestive of lung tumor, in whom final diagnosis of mycobacterial lung disease caused by Mycobacterium avium was made.
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Introduction
Mycobacteriosis is a group of diseases cau-
sed by nontuberculous mycobacteria, also called 
atypical, that includes species other than Myco-
bacterium tuberculosis. The English abbreviations 
of these bacteria such as NMT (nontuberculous 
mycobacteria) and MOTT (mycobacteria other 
than tuberculosis) are also used. Nontuberculous 
mycobacteria are widely spread in the environ-
ment, mostly in soil and water tanks, as well as in 
pipelines. For humans, these bacteria are mostly 
just saprophytes, they may colonize the airways, 
gastrointestinal tract and genitourinary tract 
[1–3]. Patients at higher risk of mycobacteriosis 
are those with chronic lung diseases (such as 
bronchiectasis, cystic fibrosis, chronic obstructi-
ve pulmonary disease (COPD), pneumoconiosis, 
pulmonary alveolar proteinosis, past pulmonary 
tuberculosis), diabetes, renal failure, pulmonary 
hypertension and the impaired immune system 
(such as individuals infected with human immu-
nodeficiency virus (HIV), following bone marrow/ 
/organ transplantation, or receiving immunosup-
pressants) [4–7].
The NTM infections most likely occur as 
a result of contact with bacteria in the environ-
ment, for example inhalation of contaminated 
water spray. To date, there is no evidence that the 
infection may be transferred between humans and 
from animals to humans, however, there are single 
reports that such transmission of M. abscessus 
may have been possible between patients with 
cystic fibrosis [7].
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COPD is characterized by a persistent limi-
tation of airflow through the lower respiratory 
tract, which usually progresses and is caused by 
excessive inflammation of the bronchi and lungs 
in response to adverse reaction to gases and dust. 
In Poland, COPD predominantly originates from 
smoking tobacco. Exacerbations and concomitant 
diseases affect the course of COPD in individual 
patients [8]. Chronic inflammation in people with 
COPD leads to changes in the structure and func-
tioning of the respiratory system, in some of the 
patients bronchiectasis are also diagnosed. COPD 
as well as bronchiectasis constitute risk factors 
for mycobacteriosis, and therefore, the disease 
should be considered in the course of diagnostics 
of newly discovered radiological changes in the 
lungs [9–12].
The present paper describes a case report 
of pulmonary mycobacteriosis mimicking neo-
plastic lung disease in a patient with COPD and 
bronchiectasis.
Case report
A 63-year-old smoking patient, with COPD 
(group B), advanced bronchiectasis and a history 
of tuberculosis in childhood was admitted to the 
hospital due to a suspected tumor located in the 
right lung. The patient has been complaining of in-
creased cough with purulent sputum expectoration, 
minor hemoptysis, dyspnea on exertion, low-grade 
fever and weight loss of 5 kg within past 6 months. 
The patient has been treated for several years with 
inhaled drugs such as beta-agonist, cholinolytic 
and corticosteroid (budesonide 800 mcg/day). 
A month before the present hospitalization, 
he was admitted to another hospital due to an 
infectious exacerbation of COPD and received 
amoxicillin/clavulanic acid, ciprofloxacin and 
doxycycline with clinical improvement. 
A chest CT scan prior to hospitalization re-
vealed a solid lesion in the segment 6 of the right 
lung measuring approximately 5 cm. The lesion 
enhanced with contrast. Furthermore, the scan 
showed a layer of fluid in the right pleural cav-
ity measuring up to 17 mm and enlarged lymph 
nodes in the right hilum up to 15 mm. Laboratory 
tests on admission did not reveal an increase 
in inflammatory markers. Capillary gasometry 
disclosed hypoxemia (pO2 58 mm Hg) with hypo-
capnia (pCO2 34 mm Hg), and oxygen saturation 
amounting to 92%. Spirometry revealed fea-
tures of severe bronchial obstruction, with FEV1 
amounting to 41% of the predicted value. X-Ray 
of the chest revealed signs of chronic bronchitis 
Figure 1A, B. Frontal and lateral chest radiographs. Emphysema. 
Bronchial wall thickening in the lower lobes. Blunting of the right 
costophrenic angle suggesting pleural effusion
A
B
and bronchiectasis with possible trace of fluid 
in the right pleural cavity (Fig. 1). A focal lesion 
described in the previous CT scan was not visible 
on the X-ray. Thus chest CT scan was repeated 
and a partial regression of the focal lesion in the 
segment 6 of the right lung was observed. At that 
time the lesion measured 17 × 32 × 20 mm and 
presented with an irregular silhouette. There 
was also a small trace of fluid in the right pleural 
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Figure 2. Axial CT image (lung window) shows a spiculated nodule in 
the sixth segment of right lower lobe mimicking primary lung cancer. 
Right-sided pleural effusion. Emphysema
Figure 3. CT scan shows nearly complete regression of nodule in the 
right lower lobe and pleural effusion after three months
cavity, the thickness of fluid layer measured up 
to 9 mm (Fig. 2). Despite the partial regression of 
the focal lung lesion, in the differential diagnosis, 
we took into account the neoplastic disease with 
the coexisting inflammatory reaction, that was 
diminished due to antibiotics use. 
Bronchoscopy was performed, and bronchial 
secretions were sampled for examination. Both 
bronchi presented with macroscopic intensive 
inflammation and scarring resulting from nodal 
perforations. Bronchial washings bacterioscopy 
targeted on acid-resistant mycobacteria and ge-
netic testing for M. tuberculosis complex were 
negative. The culture for mycobacterium was 
still under observation. Cytology of the bronchial 
secretion revealed only inflammatory cells. The 
IGRA test (Qantiferon Tb Gold) was negative.
Considering the entire clinical presenta-
tion, past tuberculosis in childhood and the 
chest CT results (characteristic location of the 
lesion), despite a negative result of the direct 
and genetic testing, the patient was diagnosed 
with tuberculosis and antituberculosis treatment 
was introduced. The patient received rifampicin 
(RMP), isoniazid (INH), and pyrazinamide (PZA). 
After ophthalmologist consultation, etambutol 
(EMB) was also administered. The patient was 
discharged with recommendation to continue 
anti-tuberculous treatment until the results of 
the culture were obtained. After 4 weeks of incu-
bation of bronchial discharge on liquid medium, 
the growth of MOTT was observed. The bacteria 
were then identified using molecular method as 
M. avium. Due to good clinical response and the 
patient’s acceptance, the treatment with RMP, INH 
and EMB was continued and PZA was stopped. 
A follow-up chest CT scan performed 3 months 
later revealed a significant regression of disease, 
the focal lesion and the pleural fluid were not 
visible (Fig. 3). After 4 months of treatment, spu-
tum cultures became negative. According to the 
guidelines [1, 2], the treatment was continued 
in an outpatient setting for 12 months from the 
moment of mycobacteria eradication.
Discussion
The prevalence of pulmonary mycobacterio-
sis is still increasing. In the United States, it is 
currently higher than prevalence of tuberculosis [7].
The increased prevalence is also influenced 
by the progress in microbiological diagnostics 
and widespread use of high-resolution computed 
tomography capable of detecting lung lesions that 
are not visible on chest X-rays. In industrialized 
countries, this increase in morbidity may also be 
related to aging of population [13].
Patients with COPD are at risk of myco-
bacteriosis development, especially those with 
coexisting bronchiectasis [13].
Among 126 subjects with COPD who un-
derwent surgical lung-volume reduction in two 
British hospitals, signs of NTM infections were 
detected in 10% of postsurgical histological ma-
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terial [14]. Basing on population studies carried 
out in Denmark, the authors concluded that in 
patients with COPD, the risk of mycobacterial 
infection is 15 times higher, and in individuals 
with bronchiectasis —187 times higher in com-
parison with the general population [7]. In every 
group, the risk increased significantly when the 
subjects received corticosteroids, and was dose
-dependent [9, 11, 12].
The presented patient had three potential 
risk factors of mycobacteriosis, namely COPD, 
bronchiectasis, and chronic inhalation of corti-
costeroid.
Huang et al. [15] demonstrated that possible 
isolation of nontuberculous mycobacteria in pa-
tients with COPD correlates with the number of 
exacerbations. In their group of patients, similarly 
to our case, MAC (Mycobacterium avium complex) 
was the most common diagnosis. Regardless of the 
predisposing factors, in many parts of the world, 
there is an increase in the incidence of MAC infec-
tion. In a study based on the data collected across 
the globe, MAC was found to be most common in 
Australia and North America, whereas in Europe, 
M. xenopii was the most frequently isolated strain 
(more often in southern Europe) [16].
Due to the high prevalence of mycobacteria in 
the human environment, proper interpretation of 
the culture result is crucial. Nontuberculous my-
cobacteria bacteria are relatively unaggressive, and 
therefore, it is necessary to differentiate between 
the disease and colonization. Mycobacteriosis is 
diagnosed in a patient fulfilling clinical, radiologi-
cal and microbiological criteria elaborated by the 
American Thoracic Society (ATS) and Infectious 
Diseases Society of America (IDSA) (Table 1) [1].
The clinical symptoms of mycobacteriosis 
in patients with chronic lung disease are masked 
by the symptoms of the underlying lung disease. 
Therefore, it is important to focus on new and 
chronic symptoms such as: weakness, fatigue, 
fever, dyspnea, hemoptysis, chest pain, slimming, 
and night sweats, which may indicate mycobac-
terial infection [3]. In the case described herein, 
the patient had experienced low-grade fever for 
several months as well as increased expectora-
tion of purulent sputum, sometimes with trace 
of blood and weight loss.
Radiologic manifestations of pulmonary my-
cobacteriosis include infiltrative and fibrotic-like 
lesions (similar to tuberculosis) or nodules and 
bronchiectasis. The most common radiological 
presentation of mycobacteriosis caused by MAC 
includes small nodules and bronchiectasis [17]. 
Studies carried out by Haiqing Chu et al. [18] 
revealed that MAC was detected more frequently 
than M. abscessus and M. kansasii in patients 
with bronchiectasis, whereas patients witho-
ut bronchiectasis were mostly diagnosed with 
M. kansasii and M. xenopii.
Single infiltrative lung lesion described on 
chest CT in the presented patient, was not typical 
of mycobacteriosis and suggested rather neoplastic 
disease, especially, in the person with a long histo-
ry of cigarette smoking. As partial regression of the 
above described lesion was observed on a second 
chest CT, performed in our department after the 
treatment with antibiotics in the previous hospital, 
we took into account the neoplastic disease with 
coexisting inflammatory pathology. However, 
lack of neoplastic infiltration in bronchoscopy, 
negative results of cytological examination of 
the sputum and bronchial secretions, as well as 
almost complete regression of chest CT pathology 
observed 3 months later, allowed for the exclusion 
of malignancy in the presented patient.
On the basis of the anamnesis, location of the 
lesion (segment 6) and bronchoscopic presenta-
Table 1. Diagnosis of nontuberculous mycobacteria lung disese [1]
Clinical criteria Microbiologic criteria
1. Pulmonary symptoms, nodular or cavitary opacities on chest 
radiograph, or an HRCT scan that shows multifocal bronchiec-
tasis with multiple small nodules
and
2. Appropriate exclusion of other diagnoses
1. Positive culture results from at least two separate expectorated 
sputum samples. (If the results from the initial sputum samples are 
nondiagnostic, consider repeat sputum AFB smears and cultures)
or
2. Positive culture results from at least one bronchial wash or lavage
or
3. Transbronchial or other lung biopsy with mycobacterial histopatholog-
ic features (granulomatous inflammation or AFB) and positive culture 
for NTM or biopsy showing mycobacterial histopathologic features 
(granulomatous inflammation or AFB) and one or more sputum or 
bronchial washings that are culture positive for NTM
HRCT — high resolution computed tomography; AFB — acid fast bacilli; NTM — nontuberculous mycobacteria
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tion, despite negative results of direct sputum 
testing for mycobacteria and negative results 
of genetic test, the patient was diagnosed with 
tuberculosis, and standard TB treatment was ad-
ministered. The diagnosis of NTMLD was made 
when the sputum culture revealed the growth of 
M. avium, 4 weeks later.
Bacteriological diagnostics of mycobac-
teriosis is mainly based on bacterioscopy and 
sputum, bronchial discharge or tissue sample 
cultures. Individual species of mycobacteria 
differ in terms of pathogenicity. The positi-
ve culture with the growth of M. kansasii or 
M. malmoense results in clinical manifestation 
in over 70% of cases. M. szulgai also presents 
with high pathogenicity. Mycobacterium avium 
complex, M. xenopii and M. abscessus manifest 
intermediate pathogenicity. The other mycobac-
teria are less pathogenic [17].
Genetic probe is an important diagnostic 
tool that detects the genome of M. tuberculosis 
complex. Genetic testing is particularly indicated 
in patients with positive result of bacterioscopy, 
when it allows to differentiate quickly between 
tuberculosis and mycobacteriosis.
In the case we describe, the genetic test 
was negative, and therefore, it did not have any 
clinical significance. A positive result may have 
supported the diagnosis of tuberculosis.
Tuberculin skin testing (TST) and IGRA 
testing are not very useful in the differential dia-
gnosis of mycobacteriosis and active tuberculosis. 
The TST test may be positive in NTM disease, be-
cause M. tuberculosis and all NTM have the same 
antigens as the entire strain of mycobacterium. 
Patients with NTM infections usually have negati-
ve IGRA test results. M. kansasii, M. marinum and 
M. shulgai are the exceptions, since they belong 
to a few NTMs, which — similarly to the M. tu-
berculosis — produce ESAT-6 and CFP-10 proteins 
used as antigens in IGRA tests [19]. The negative 
result of IGRA in the presented patient did not 
rule out active tuberculosis and did not have any 
clinical utility in case of mycobacteriosis. Only 
microbiological examinations are important in 
differentiation between mycobacterial infection 
and tuberculosis.
 Treatment of patients with mycobacteriosis 
is difficult. In most cases multidrug regimes are 
used according to the guidelines of ATS and 
BTS [1, 2]. Due to long duration of treatment 
(12 months since negative culture result) and 
possible adverse effects of administered drugs, the 
risk and benefits of treatment should be evaluated 
individually for each patient.
In the case we describe, despite the low patho - 
genicity of M. avium, it was decided to continue 
the therapy, due to the symptomatic course of the 
disease and good treatment tolerability.
In MAC infections, the routine treatment 
includes macrolide and etambutol with rifam-
picin. In severe cases, aminoglycoside should 
be added. Sometimes patients undergo surgery. 
The treatment results have significantly improved 
after implementation of new macrolides such as 
clarithromycin and azithromycin [20].
The patient described in our case study initial-
ly received RMP, INH, EMB and PZA because 
tuberculosis was suspected. After having received 
a positive culture for M. avium, pyrazinamide was 
discontinued, and the other drugs were maintained.
Treatment of mycobacteriosis requires strict 
control in the outpatient settings, as it is a long-
term process. In addition, serial direct sputum 
examinations and cultures are necessary. Clinical 
improvement and negative culture should be ob-
tained after 3–6 months of treatment [1, 2]. The 
therapy should be continued for one year after 
the negative culture result [1, 2].
In the case we describe, the patient respon-
ded well to treatment. After 4 months almost 
complete regression of radiological features of 
disease and negativization of sputum cultures 
were observed, thus the previously administered 
treatment was continued for the next 12 months.
Mycobacteriosis should be always considered 
in all patients with risk factors who are hospita-
lized due to new clinical symptoms and radio-
logical characteristics in the lungs. Diagnosis of 
mycobacteriosis in the course of chronic lung 
condition may be especially difficult, and there-
fore, doctors should be aware of this possibility.
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